News coverage about Athersys (NASDAQ:ATHX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Athersys earned a news impact score of 0.21 on Accern’s scale. Accern also assigned headlines about the biopharmaceutical company an impact score of 45.3299935284703 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s analysis:

A number of brokerages recently weighed in on ATHX. Zacks Investment Research upgraded shares of Athersys from a “hold” rating to a “buy” rating and set a $2.25 price target for the company in a research note on Thursday, September 7th. Maxim Group reiterated a “buy” rating and set a $12.00 price target on shares of Athersys in a research note on Friday, September 1st.

Shares of Athersys (NASDAQ:ATHX) opened at 1.99 on Wednesday. The company’s 50-day moving average is $1.67 and its 200-day moving average is $1.50. The firm’s market cap is $226.68 million. Athersys has a 52 week low of $1.02 and a 52 week high of $2.30.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). Athersys had a negative net margin of 729.07% and a negative return on equity of 121.47%. The company had revenue of $0.67 million during the quarter, compared to the consensus estimate of $0.96 million. During the same quarter in the previous year, the company posted ($0.08) earnings per share. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. Analysts forecast that Athersys will post ($0.24) EPS for the current fiscal year.

In other news, EVP John J. Harrington sold 36,000 shares of the business’s stock in a transaction on Friday, June 16th. The shares were sold at an average price of $1.45, for a total transaction of $52,200.00. Following the completion of the transaction, the executive vice president now owns 712,743 shares of the company’s stock, valued at $1,033,477.35. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 9.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at

Athersys Company Profile

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Stock Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related stocks with our FREE daily email newsletter.